Atomwise Appoints Steve Worland as CEO to Lead AI-Driven Drug Discovery

Atomwise has appointed Steve Worland, Ph.D., as its new Chief Executive Officer. Worland brings over 30 years of experience in biotechnology and pharmaceuticals to the AI-driven drug discovery company.

Atomwise has appointed Steve Worland, Ph.D., as its new Chief Executive Officer, announced in a press release. Worland, who has over 30 years of experience in the biotechnology and pharmaceutical sectors, will work with Atomwise's management and board to advance the company's AI-driven drug discovery platform, AtomNet.

Worland's extensive background includes leadership roles at eFFECTOR Therapeutics, Anadys Pharmaceuticals, and Pfizer. His scientific contributions have been pivotal in the development of several clinical-stage products. At Atomwise, he aims to leverage his expertise to enhance the company's proprietary pipeline and optimize its AI capabilities for drug discovery.

Additionally, Atomwise has appointed Mike Varney, Ph.D., as Lead Independent Director of the Board. Varney, a seasoned biotech leader, brings his experience from Genentech and Pfizer to support Atomwise's mission of revolutionizing small molecule drug discovery through AI.

We hope you enjoyed this article.

Consider subscribing to one of several newsletters we publish. For example, in the Daily AI Brief you can read the most up to date AI news round-up 6 days per week.

Also, consider following our LinkedIn page AI Brief.

Subscribe to Daily AI Brief

Daily report covering major AI developments and industry news, with both top stories and complete market updates

You May Also Like